Videos

How FDA priority review vouchers speed psychedelic therapy approvals.

Oral zervimesine blocks toxic amyloid and alpha-synuclein oligomers, as Cognition maps FDA strategy for Lewy body trials.

CT-1812 shows promise in Lewy body dementia, stabilizing hallucinations and delusions while easing caregiver distress.

Learn how genetics shape psych med response and dosing.

HHS targets “psychiatric overprescribing,” but experts urge thoughtful deprescribing—stopping ineffective medications while replacing them with evidence-based alternatives tailored to patients.

Tracy Hicks, DNP, FNP/PMHNP-BC, outlines how personalized, team-based care and shared decision-making can improve schizophrenia outcomes in real-world practice.

Learn how to better assess and manage behavioral and psychological symptoms of Alzheimer disease dementia.

The SPAN survey underscores gaps in schizophrenia care access as new treatments emerge, citing coverage and continuity challenges.

Auvelity is now approved for the treatment of Alzheimer disease agitation. Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP, weighs in.

FDA approves Axsome’s AXS-05 for Alzheimer’s agitation, backed by multiple trials.

A multicenter study tests SAINT TMS for postpartum depression.

Interim analysis suggests tazbentetol may regrow synapses, improving cognition and schizophrenia symptoms.

Learn how clinicians safely add esketamine nasal spray: REMS setup, two-hour monitoring, vitals checks, referrals, and patient-centered collaboration.

Learn how clinics start esketamine safely: REMS setup, two-hour monitoring, vitals, risk screening, and referral-friendly team care.

AFSP and JED plan a 2026 merger, uniting $75M resources to expand suicide prevention research, school programs, and support for all ages.

DT120, a pharmaceutical-grade formulation of LSD, shows rapid, lasting anxiety relief—single dose, no therapy—with 48% remission at 12 weeks.

Sleep disorders commonly occur in young patients with ADHD. See how to monitor and treat these issues.

Definium’s CMO says FDA talks stay aligned with their plans for advancing DT120 ODT for the treatment of depression, anxiety, and now PTSD.

Learn why patients skip psych meds and how to boost adherence with stigma-free dialogue, routine hacks, family support, and deprescribing tips.

Experts explain why most narcolepsy patients need combination therapy, not one pill, and how new agents cut daytime sleepiness toward normal.

Depression care speeds up when clinicians measure symptoms, adjust doses fast, and tackle side effects—helping patients reach remission sooner.

Clinicians urge faster, data-driven depression care—optimize doses, switch sooner, track PHQ-9 and side effects to reach remission quicker.

Emerging student researchers share their award-winning neuroscience and psychiatry projects.

"While studying the CAT scan, I picture Groucho Marx as Dr. Hugo Z. Hackenbush..."

Discover how art, film, and poetry return to the APA meeting—and why psychiatrists practice creativity in every patient encounter.

Experts share more on research developments of remternetug for Alzheimer disease.

How clinicians choose TRD care: patient preferences, access barriers, and rapid glutamatergic options like esketamine for suicidal depression.

Learn how DEA scheduling shapes narcolepsy treatment choices, and why emerging orexin agonists may transform daytime sleepiness and cataplexy care.

Experts explain which narcolepsy meds suit kids—oxybates and pitolisant approvals, stimulant side effects, and key heart-safety checks.

How clinicians choose TRD treatments: patient preference, esketamine vs brain stimulation, and fast-acting glutamate options that improve function.